Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B49: pembrolizumab plus chemotherapy versus placebo plus chemotherapy in PD-L1-positive HR-positive/HER2-negative unresectable locally recurrent or metastatic breast cancer
CTR20212416Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in breast cancer, sponsored by Merck & Co.. Started Sep 2022; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20212416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212416.